Trials / NCT05392179
A Study in Subjects With Retinitis Pigmentosa
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Aldeyra Therapeutics, Inc.
- Treatment
- ADX-2191; ADX-2191
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 8 participants
- Started
- 2022-07-14
- Main results expected
- 2023-06-23
- Results posted
- Yes
- Record last updated
- 2026-04-23
What the study is testing
An open-label Phase II clinical trial, 8 (eight) subjects with retinitis pigmentosa due to rhodopsin mutations (including P23H) will be identified and treated with serial intravitreal injections of ADX-2191 in the worse seeing eye. Ocular structure and function will be evaluated.
Where it runs
United States (1)
- Duke Eye Center, Durham, North Carolina